Trial site staff shortages, sluggish patient recruitment force Addex to scrap phase 3 Parkinson's study

Addex Therapeutics waited more than a decade for the chance to learn whether dipraglurant is effective in dyskinesia associated with Parkinson’s disease (PD-LID), suffering delay after delay as it tried to get a late-phase trial started. After all that, the phase 2b/3 study has crashed out before delivering data because “COVID-19 related patient concerns about participation in clinical studies as well as staffing shortages and turnover within study sites” made enrollment intolerably slow.